Current Report Filing (8-k)
June 27 2017 - 5:02PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the
Securities Exchange Act of
1934
Date of report (Date of earliest
event reported):
June 26, 2017
Checkpoint Therapeutics, Inc.
(Exact Name of Registrant as Specified
in Charter)
Delaware
(State or Other Jurisdiction
of Incorporation)
|
000-55506
(Commission File Number)
|
47-2568632
(IRS Employer
Identification No.)
|
2 Gansevoort Street, 9th Floor
New York, New York
(Address of Principal Executive
Offices)
(781) 652-4500
(Registrant's telephone number,
including area code)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act.
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act.
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 3.01.
|
Transfer of listing.
|
On June 26, 2017, Checkpoint
Therapeutics, Inc. (the “Company”), a Fortress Biotech company, announced that its common stock commenced trading on
the Nasdaq Capital Market under the symbol “CKPT” at the open of the U.S. financial markets on June 26, 2017. Upon
commencement of trading on Nasdaq, Checkpoint’s common stock ceased trading on the OTCQX Best Market. A copy of the press
release is attached as Exhibit 99.1 to this Item and is incorporated herein by reference.
Item 9.01
|
Financial Statements And Exhibits.
|
(d)
|
Exhibits.
|
|
|
99.1
|
Press release issued by Checkpoint, dated June 26, 2017.
|
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
Checkpoint Therapeutics, Inc.
|
|
(Registrant)
|
|
|
|
|
|
|
Date: June 27, 2017
|
|
|
|
|
|
|
By:
|
/s/ James F. Oliviero
|
|
|
James F. Oliviero
|
|
|
President and Chief Executive Officer
|
INDEX
TO EXHIBITS
Exhibit
|
|
|
Number
|
|
Description
|
|
|
|
99.1
|
|
Press release issued by Checkpoint, dated June 26, 2017.
|